Cancer Genetics (NASDAQ: CGIX) (“CGI”) has entered into a strategic partnership with Mendel Health, an artificial intelligence company focused on using the Mendel.ai deep-learning engine to accelerate and constantly update clinical trial matching for patients. The companies will be collaborating to integrate Mendel.ai capabilities for clinicians, oncologists and pathologists, as well as cancer centers and hospitals with CGI’s disease-focused reports and testing results. The companies anticipate that initial, early-access partners will be using the system during the second quarter of 2017 with a more extensive rollout through the third and fourth quarters of this year. “Artificial intelligence has advanced and impacted nearly every industry, and we believe it has the promise to transform laboratory based medicine. In an era where there is tremendous need to advance the innovative new therapies in unfilled trials with precisely matched patients that meet these increasingly complex enrollment criteria, Mendel.ai offers a timely, high-impact and ready-to deploy solution that we believe will make CGI more valuable to our customers and drive value for our shareholders,” CGI’s CEO and president Panna Sharma stated in the news release.
To view the full press release, visit: http://nnw.fm/XmGV2
About Cancer Genetics, Inc.
Cancer Genetics, Inc. is engaged in enabling precision medicine for oncology through the use of molecular markers and information. CGI is developing a global footprint with locations in the US, India and China. The company has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute. The company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. For more information, please visit www.cancergenetics.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer